{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970849",
  "id": "02970849",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250721",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lz4x75sqsqrl.pdf",
  "summary": "### **Material Information Summary: Clinical Trial Update**  \n- **Phase I trial completion**: Final participants in Cohort 6 dosed and discharged; dosing phase fully completed.  \n- **Safety data**: No adverse safety signals or dose-limiting toxicities observed to date.  \n- **Next steps**: Final clinical study report expected by **September 2025 quarter**; SRC review pending full pharmacokinetic data.  \n- **Context**: Reinforces confidence in safety profile for **Xolatryp\u2122**, supporting progression to Phase II.  \n\n### **Previous Key Catalysts** (from appended updates):  \n- **Preclinical efficacy**: Demonstrated **42% cardioprotection** (CHD study, May 2025) and **statistically significant neuroprotection** (TBI study, April 2025).  \n\n**No material financial or capital structure impacts identified.**",
  "usage": {
    "prompt_tokens": 2137,
    "completion_tokens": 176,
    "total_tokens": 2313,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T22:44:00.475889"
}